Lung Cancer

Top Story

ASCO expands enrollment for TAPUR study

ASCO expands enrollment for TAPUR study
November 17, 2017

ASCO announced four cohorts of Targeted Agent and Profiling Utilization Registry, or TAPUR, will enroll additional patients with a variety of cancers.

The combination of nivolumab (Opidvo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) also is being added to the study, bringing the number of drugs evaluated to 19, with 16 different targeted therapy options.

Meeting News

Women underutilize CT scans for lung cancer

November 17, 2017
Women were less likely to use CT scans for lung cancer screening than men, even though they are higher risk than men for the disease, according to a presenter at CHEST…
Meeting News

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

November 16, 2017
WASHINGTON — When diagnosed with Hodgkin lymphoma at…
FDA News

FDA authorizes IMPACT test to rapidly identify cancer mutations

November 15, 2017
The FDA today authorized Integrated Mutation Profiling of Actionable Cancer Targets, or IMPACT, an in vitro diagnostic test that uses next-generation sequencing to…
More Headlines »
CME

Expert Update: What's New in Essential Thrombocythemia

This activity is supported by an educational grant from Incyte Corporation.

Appropriate early diagnosis and initiation of therapy is essential in the management of myeloproliferative neoplasms…
More »
Video
Meeting News

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
More »
Resource Centers

CME

Expert Perspectives: The Latest Evidence Regarding Immune Checkpoint Inhibitors for Advanced Bladder Cancer

This activity is supported by an educational grant from Merck & Co., Inc.

In 2016, the first immune checkpoint inhibitor was approved by the US Food and Drug Administration (FDA) for the…
More »